secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001104659-25-044349
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q1 net revenue down 27.6% to $10.7M; cash $349.7M, runway to 2028
--------------------------------------------------------------------------------

- Net loss of $64.1M ($0.38 per share) vs. $64.8M ($0.49) in Q1 2024; R&D expenses doubled to $42.9M on wet AMD trials.
- DEXTENZA sales fell 27.7% to $10.6M due to pricing strategy, MIPS inclusion; quarterly sales expected to rise for rest of 2025.
- SOL-1 (Phase 3 wet AMD) topline data on track for 1Q 2026; FDA accepted SPA amendment allowing re-dosing at Weeks 52 and 76.
- SOL-R enrollment strong after target cut to ~555 subjects; remains 90% powered for non-inferiority; expedited NDA submission possible.
- Positive FDA feedback on potential AXPAXLI registrational trial in NPDR; company planning next steps in NPDR and DME.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/0001104659-25-044349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer